JCO PO author Dr. Philip Philip at Henry Ford Cancer Institute and Wayne State University shares insights into his JCO PO article, “Incorporating Circulating Tumor DNA Testing Into Clinical Trials: A ...

Regeneron's Dupixent leads growth as Eylea sales decline and valuation is attractive, but growth is delayed by 2-3 years.

Those threats are just one example of the rising incidence of patient incivility in health care. Sexual harassment, misogyny, ...

Patients with rare diseases are increasingly working to find and fund their own cures. But should they have to?

A volatile stock market represents an ideal opportunity for long-term investors to pounce.

Once relegated to the fringes of beauty culture, tanning beds are back – and they’ve had a wellness glow-up, with terms such as ‘responsible tanning’ and beds fitted with infrared light. WH asks if ...

Authors of Journal of Clinical Oncology Editorials, Review Articles, Podcasts, Understanding the Pathway (UTP), and Oncology Grand Rounds (OGR) articles may not have stock, employment, or speakers ...

BURLINGAME, CA, UNITED STATES, June 26, 2025 /EINPresswire.com/ -- Fast Melt Tablets Market is estimated to be valued at US$ 6.20 Bn in 2025 and is expected to reach US$ 11.41 Bn ...

The positive CHMP opinion is based on data from the CABINET Phase III trial, which investigated Cabometyx versus placebo in people living with advanced pNETs or epNETs, whose disease had progressed ...